Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunkai Yu

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasShivaani Kummar, Martin E Gutierrez, Alice Chen, et al.
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
The Lancet. Oncology|January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan, Corey A Carter, Arlene Berman, et al.
Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Cell Reports. Medicine|July 14, 2026
Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancersMeijie Tian, Katrina Jia, Jerry T Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasShivaani Kummar, Martin E Gutierrez, Alice Chen, et al.
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
The Lancet. Oncology|January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan, Corey A Carter, Arlene Berman, et al.
Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Cell Reports. Medicine|July 14, 2026
Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancersMeijie Tian, Katrina Jia, Jerry T Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
Pageof 5